2026 Q1 -tulosraportti
69 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenUpdate from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.
- ·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.
Once again, hot air from your side - life is too short to waste on your complaints. - ·22.7.Have you eaten nails - and put 222.000 at stake for 1.25 come forward and tell who you are - but you probably don't dare.You are right that when there are not so many shares for sale, it seems like a wall, that's what it's also called. There can be several reasons for selling, but here during the summer holiday, when everything is at a low ebb, people start to get bored, and for something to happen, one starts either selling and / or buying shares. To be honest, it's only because I know that positive news from Bioporto is coming soon that I am staying away from the sell button. On the other hand, when there are not so many shares for sale, it means that the majority are holding onto the shares in their portfolio.
·20.7.Excerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1I am aware that FDA's approval is naturally an important event,, but there will be revenue from the USA while the research is ongoing, because the large treatment centers will utilize the CLIA system. Also, when KDIGO soon, expectedly 1-2 months, finishes with the mentioned documents, then the hospitals and treatment centers that have received the strongest recommendation will also start buying NGAL test, because they must have it as a fixed routine in their treatment routine. I have no doubt that Bioporto will comply with the guidance they have announced.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
69 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenUpdate from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.
- ·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.Once again, hot air from your side - life is too short to waste on your complaints.
- ·22.7.Have you eaten nails - and put 222.000 at stake for 1.25 come forward and tell who you are - but you probably don't dare.You are right that when there are not so many shares for sale, it seems like a wall, that's what it's also called. There can be several reasons for selling, but here during the summer holiday, when everything is at a low ebb, people start to get bored, and for something to happen, one starts either selling and / or buying shares. To be honest, it's only because I know that positive news from Bioporto is coming soon that I am staying away from the sell button. On the other hand, when there are not so many shares for sale, it means that the majority are holding onto the shares in their portfolio.
- ·20.7.Excerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1I am aware that FDA's approval is naturally an important event,, but there will be revenue from the USA while the research is ongoing, because the large treatment centers will utilize the CLIA system. Also, when KDIGO soon, expectedly 1-2 months, finishes with the mentioned documents, then the hospitals and treatment centers that have received the strongest recommendation will also start buying NGAL test, because they must have it as a fixed routine in their treatment routine. I have no doubt that Bioporto will comply with the guidance they have announced.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
69 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenUpdate from TED. Tenders for NGAL-tests have now started to emerge (there have been no tenders here over the summer). The current tender is designed based on KDIGO's new recommendations as well as the machines validated for the test. However, it will be a few months before we find out if it is BioPorto's test that wins the order, as the formal EU tender rules and deadlines must be complied with.
- ·23.7. · MuokattuImpressive. The closing auction opens with a match at a price of 1.185 for a total of 47 shares. Interesting if it holds until 16.59. Yesterday there was no match and the turnover currently indicates almost 50 kr today. What "progress". Lesson: Investing in illiquid shares is associated with a high risk that one trades the share at an unfair price.Once again, hot air from your side - life is too short to waste on your complaints.
- ·22.7.Have you eaten nails - and put 222.000 at stake for 1.25 come forward and tell who you are - but you probably don't dare.You are right that when there are not so many shares for sale, it seems like a wall, that's what it's also called. There can be several reasons for selling, but here during the summer holiday, when everything is at a low ebb, people start to get bored, and for something to happen, one starts either selling and / or buying shares. To be honest, it's only because I know that positive news from Bioporto is coming soon that I am staying away from the sell button. On the other hand, when there are not so many shares for sale, it means that the majority are holding onto the shares in their portfolio.
- ·20.7.Excerpt from Dagbladet Børsen today: "Lottery ticket or golden egg? Biotech stock could be facing a turning point" "When Carsten Buhl says that now is the time, he bases it on Bioporto having chosen to enter into a dialogue with FDA, the American health authorities, about what is required for the company to obtain the important approval. That dialogue meant that Bioporto is now conducting a larger validation study. The company announced this on June 9, and it pushed the timeline for approval into mid-2028, whereas it previously should have been by the end of 2027." ""It is a scalable business. There are costs in developing the product, but once we have it and have approval, profitability can come quite quickly," "No one is as far along as we are in terms of obtaining FDA approval (the American health authorities, ed.). Regardless of whether you have a lot of money, as some players do, there is a time factor. There are no shortcuts," says Carsten Buhl. https://borsen.dk/nyheder/investor/lottokupon-biotekaktie-nede-65-pct-har-jagtet-vendepunkt-in-ti-ar?b_source=bioporto&b_medium=row_1&b_campaign=list_1I am aware that FDA's approval is naturally an important event,, but there will be revenue from the USA while the research is ongoing, because the large treatment centers will utilize the CLIA system. Also, when KDIGO soon, expectedly 1-2 months, finishes with the mentioned documents, then the hospitals and treatment centers that have received the strongest recommendation will also start buying NGAL test, because they must have it as a fixed routine in their treatment routine. I have no doubt that Bioporto will comply with the guidance they have announced.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt